Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News on Pharma

Regeneron Dives As Amgen Tees Up Its Rival To Moneymaking Machine Eylea

Regeneron stock toppled Monday after a judge unexpectedly rejected a request that would have prevented Amgen from launching an Eylea copycat.

Investors Business Daily

Minister vows 'assertive' approach on vape crackdown

While a ban on vape sales is starting to have an effect, Health Minister Mark Butler says further action is needed on stores that are illegally selling them.

AAP

Apellis Stock Hammered After Eye Drug Gets A Third European Rejection

European regulators rejected Apellis Pharmaceuticals' embattled eye drug, Syfovre, and Apellis stock tumbled to a month-low.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

2024 Election: Drug Prices Remain A 'Hot Topic.' Can Pharma Stocks Withstand The Pressure?

Pharmaceutical stocks largely shook off the brunt of negotiated drug prices. But that doesn't mean they'll be spared election noise.

Investors Business Daily

Gavi secures 500,000 doses of mpox vaccine for Africa amid outbreak

The Gavi vaccine alliance has reached an agreement with Danish pharmaceutical company Bavarian Nordic to obtain 500,000 doses of mpox vaccine for African countries dealing with an outbreak of the virus.

Radio France Internationale

How BioNTech, Up 26% Over Four Days, Is Riding Summit's Coattails To A Recovery

BioNTech stock has climbed 26% over four days as the German biotech rides a round of cancer treatment success from Summit Therapeutics.

Investors Business Daily

DEA shutting down two offices in China even as agency struggles to stem flow of fentanyl chemicals

The U.S. Drug Enforcement Administration is closing two of its offices in China, a move that comes even as the agency struggles to disrupt the flow of precursor chemicals from the country that have fueled a fentanyl epidemic

The Independent UK

Read news from The Economist, FT, and more,
with one subscription

Nuvalent Flies On 'Multibillion-Dollar' Potential, While Iteos Crashes On Patient Deaths

Biotech stocks Nuvalent and Iteos diverged Monday on updates for their lung cancer treatments at the ESMO meeting in Madrid.

Investors Business Daily

Bausch Reportedly Explores A Sale; Could Alcon, J&J Or AbbVie Buy It?

Bausch + Lomb stock surged Monday — briefly breaking out — on a report the company is working with advisors to explore a potential sale.

Investors Business Daily

Ascendis Rockets — And Hammers BioMarin — On New Results For Growth Drug

Ascendis Pharma stock rocketed Monday on promising test results for a growth treatment that could rival BioMarin's approved drug, Voxzogo.

Investors Business Daily

Gilead’s biannual HIV shot reduced risk of infections by 96 percent, company says

The drugmaker said its injections were 89 percent more effective than its own Truvada

The Independent UK

Moderna's Pain Continues Amid Flurry Of Downgrades Following 'Tough' R&D Day

Moderna stock tumbled again Friday on a series of downgrades and price-target cuts following a "tough update" at its R&D Day.

Investors Business Daily

Gilead Sciences Pops On A New $4 Billion Opportunity In HIV Prevention

Gilead stock popped Thursday after the biotech giant said its twice-yearly shot prevented 99.9% of HIV infections in a study.

Investors Business Daily

Moderna Stock Plunges as Vaccine Maker Slashes R&D Budget: What to Know

Moderna stock is plunging Thursday after the COVID-19 vaccine maker announced plans to drastically cut its R&D spending to focus on new product approvals.

Kiplinger

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Summit Therapeutics, With 85% Gain This Week, Rockets Again On $235 Million Sale

Summit Therapeutics stock rocketed again Thursday — adding onto an 85% gain this week — after raising $235 million in a private placement.

International Business Times

J&J CEO Slams Biden's Drug Pricing Law, Says It Will 'Chill' Innovation

J&J CEO explained that the new drug-price negotiation law threatens development of new drugs, according to Bloomberg.

Investors Business Daily

Moderna Crashes After Slashing Its R&D Budget, Issuing Light Guidance

Moderna stock crashed Thursday after the Covid vaccine maker slashed its R&D budget and issued a light sales view.

Investors Business Daily

Biotech Stock Near Buy Point Amid Impressive Sales Track Record

Rhythm Pharmaceuticals is near a buy point after strong sales in the second quarter.

Get all your
news in one place.

100’s of premium titles.
One news app.

The Independent UK

British company deliberately hiked price of life-saving drug, court rules

The NHS was forced to spend over £80m a year on hydrocortisone tablets after the price was rigged

Investors Business Daily

Travere Stock Pops After Snagging Full Approval For Calliditas Rival In Kidney Disease

Travere Therapeutics stock surged Friday after the biotech company snagged full FDA approval for its kidney disease treatment, Filspari.

AAP

Patient warning over plan to ease GP load with pharmacy

The peak body for GPs has hit out at a NSW government plan to let pharmacies treat more health conditions to take pressure off doctors.

StockNews.com

3 Undervalued Healthcare Stocks With Strong Upside Potential

The healthcare sector is set for robust growth, driven by surging demand for quality treatments, a growing patient base, breakthroughs in biopharma, and supportive policies. Therefore, investors could consider undervalued pharmaceutical stocks like Merck & Co. (MRK), Pfizer (PFE), and Cigna (CI) with significant upside potential. Read more.

The Independent UK

5 takeaways from AP's report on the big backlog of uninspected drug factories

Nearly five years after COVID-19, a new analysis by The Associated Press shows that U.S. regulators are struggling to address a massive backlog of uninspected pharmaceutical plants

The Independent UK

Nearly 2,000 drug manufacturing plants are overdue for FDA inspections after COVID delays, AP finds

U.S. health inspectors are still struggling to address a massive backlog of pharmaceutical plants that went uninspected during disruptions caused by COVID-19

Investors Business Daily

How Lilly, Novo Could Beat Tesla To The Trillion-Dollar Club; Plus, Nvidia's Battle With Microsoft, Apple

Weight-loss drug kingpins Eli Lilly and Novo Nordisk could join the trillion-dollar company club before even Tesla, according to a report.

1 … 17 18 19 20

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.